First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase) to be shared in a late-breaking oral presentation Four-year data ...
Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
In the first ever disclosure for the subcutaneous formulation of Opdivo, the CheckMate -67T Phase 3 trial demonstrates activity in advanced or metastatic clear cell renal cell carcinoma Company plans ...
Bristol Myers Squibb Co (NYSE:BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or ...
BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Halozyme ...
The CheckMate 67T trials revealed that subcutaneous nivolumab was noninferior to intravenous nivolumab for the treatment of advanced or metastatic clear cell renal cell carcinoma. Subcutaneous ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback